## Niraj Shenoy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8173999/publications.pdf Version: 2024-02-01



NIDAL SHENOV

#	Article	IF	CITATIONS
1	Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell, 2018, 34, 700-706.	16.8	154
2	Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood, 2014, 124, 873-881.	1.4	100
3	High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1666-1677.	7.1	91
4	Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?. BMC Medicine, 2020, 18, 260.	5.5	88
5	Role of DNA methylation in renal cell carcinoma. Journal of Hematology and Oncology, 2015, 8, 88.	17.0	76
6	Alterations in the ribosomal machinery in cancer and hematologic disorders. Journal of Hematology and Oncology, 2012, 5, 32.	17.0	68
7	Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. Journal of Clinical Investigation, 2019, 129, 1612-1625.	8.2	64
8	Kidney Cancer Is Characterized by Aberrant Methylation of Tissue-Specific Enhancers That Are Prognostic for Overall Survival. Clinical Cancer Research, 2014, 20, 4349-4360.	7.0	60
9	Functional succinate dehydrogenase deficiency is a common adverse feature of clear cell renal cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	30
10	Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 1999-2003.	1.3	28
11	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Laboratory Investigation, 2017, 97, 494-497.	3.7	24
12	lmmune evasion in renal cell carcinoma: biology, clinical translation, future directions. Kidney International, 2021, 99, 75-85.	5.2	22
13	HIF1α is not a target of 14q deletion in clear cell renal cancer. Scientific Reports, 2020, 10, 17642.	3.3	10
14	Aggressive myoepithelial carcinoma with EWSR1â€POU5F1 fusion highly responsive to Ewing sarcoma combination chemotherapy. Cancer, 2020, 126, 5198-5201.	4.1	7
15	Epigenetic dysregulation by aberrant metabolism in renal cell carcinoma can be reversed with Ascorbic acid. Molecular and Cellular Oncology, 2019, 6, 1595309.	0.7	6
16	Corticosteroid-resistant bulbar neurosarcoidosis responsive to intravenous immunoglobulin. Practical Neurology, 2015, 15, 289-292.	1.1	5
17	The Regulation and Interactions of the Hypoxia Inducible Factor Pathway in Carcinogenesis and Potential Cancer Therapeutic Strategies. Journal of Cancer Therapy, 2015, 06, 511-521.	0.4	4
18	Protocol Modification To Determine The Cytotoxic Potential Of Drugs Using Cell Viability Assays That Rely On The Reducing Property Of Viable Cells. Protocol Exchange, 0, , .	0.3	3

NIRAJ SHENOY

#	Article	IF	CITATIONS
19	Is ADRM1 a Good Target for Cancer Therapy?. Acta Haematologica, 2015, 134, 86-87.	1.4	2
20	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. Clinical Genitourinary Cancer, 2018, 16, e1117-e1122.	1.9	1
21	Professional ethics in academia: defining the categories of behavior spectrum in matters of unethical conduct. International Journal of Ethics Education, 2019, 4, 193-194.	0.9	1